The PREP Act’s Role in Shielding Big Pharma and Incentivizing Harmful COVID-19 Treatments
Imagine waking up one morning during the COVID-19 pandemic, eager to resume life as normal, and you decide to get the COVID-19 injection at your local pharmacy. In the name of “trusting the science,” you follow government guidelines and roll up your sleeve. But what happens when things go wrong? What happens if you’re suddenly […]
Only 14 Percent of American Adults Have Received Updated COVID Booster Shots
Only 13.9 percent of the U.S. adult population have rolled up their sleeves for the updated COVID-19 shot, according to the U.S. Centers for Disease Control and Prevention (CDC). The mRNA monovalent COVID booster shot, approved by the U.S. Food and Drug Administration (FDA) on Sept. 11, 2023 despite only being tested on mice, was […]
One in Five Paxlovid Users Experience COVID Rebound Infections
A new study published earlier this month suggests that people who took Pfizer’s Paxlovid (nirmatrelvir-ritonavir)—an antiviral drug treatment for COVID-19—are much more likely to experience reinfection than those who did not take the drug. The study, published in the Annals of Internal Medicine, reported that one in five people who take Paxlovid could experience rebound […]
Merck’s COVID Anti-Viral Drug May Cause SAR-CoV-2 to Mutate
Scientists have found evidence to suggest that an anti-viral COVID-19 drug manufactured by Merck & Co. being used to treat COVID may be causing the SARS-CoV-2 virus to mutate and create new variants of the virus for which humans could have no immunity.1 The mechanism of action of the drug molnupiravir, a pill also sold […]
Merck and Pfizer Seek Approval for COVID-19 Antiviral Drugs
Merck and Pfizer have submitted Emergency Use Authorization (EUA) applications to the U.S. Food and Drug Administration (FDA) to authorize distribution of what would be the first antiviral drug specifically designed to treat COVID-19 disease.1 Merck/Ridgeback Biotherapeutics are seeking EUA approval for Molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral drug originally developed to treat influenza.2 Pfizer […]
